Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

18F-FSPG Positron Emission Tomography to Predict Response or Resistance to Yttrium-90 Treatment in Hepatocellular Cancer Patients

Trial Status: approved

This phase I trial studies whether 18F-FSPG positron emission tomography (PET) can be used to predict response or resistance to yttrium-90 (Y90) treatment in hepatocellular carcinoma (HCC) patients. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, 18F-FSPG. 18F-FSPG is specifically taken up by the tumor cells via the system xC-transporter (xCT). Upon uptake, xCT activity can be assessed and tumor cells can be detected and imaged by PET. Since elevated xCT activity is a sign of resistance to radiation therapy and 18F-FSPG PET identifies xCT activity, 18F-FSPG PET may be an effective way to predict response or resistance to Y90 treatment in HCC patients.